ANXA2 and ovarian cancer: The results revealed that exosomal ANXA2 derived from ovarian cancer could confer tumour characteristics to HMrSV5 cells and regulate MMT and extracellular matrix degradation of HMrSV5 cells, finally forming pre‐metastasis microenvironment suitable for intraperitoneal implantation and metastasis of ovarian cancer, which not only provide new insights into the molecular mechanism of intraperitoneal implantation and metastasis of ovarian cancer, but may also guide the development of therapeutic treatments to delay or inhibit tumour metastasis.